Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2026
Reporting Period: Specific event date of January 7, 2026.
Key Financial Metrics
- Cash Inflow: Received $18 million from Scilex Holdings Inc., representing full satisfaction of obligations under an Option Agreement.
- Dividend Declaration: Board approved a cash dividend of $0.25 per share.
- Total Dividend Distribution: Approximately $10.5 million based on current shares outstanding.
- Liquidity Source: Dividend to be funded with surplus capital.
- Payment Dates: Record date is January 16, 2026; payment date is January 26, 2026.
Material Changes
The filing reports a significant change in the company's capital structure and cash position due to the receipt of the $18 million payment from Scilex Holdings Inc. Additionally, the company is initiating a cash distribution to shareholders, marking a shift from capital preservation to capital return.
Outlook and Management Commentary
Management, represented by President and CEO Nadav Kidron, characterized the dividend as a reward to stockholders. The company explicitly stated that the dividend will be funded using surplus capital, implying that the recent $18 million inflow has strengthened the balance sheet sufficiently to support this distribution without jeopardizing operational liquidity. No forward-looking revenue guidance or specific operational milestones were detailed in this specific filing.
Investor Verification Checklist
- Verify the exact number of shares outstanding to confirm the $10.5 million aggregate dividend calculation.
- Review the attached Press Release (Exhibit 99.1) for details on the Option Agreement with Scilex Holdings Inc.
- Confirm the company's remaining cash balance post-dividend to assess ongoing operational runway.
- Check for any tax implications of the dividend for shareholders in different jurisdictions.